Principal Financial Group Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$19.36 - $29.54 $2.59 Million - $3.95 Million	-133,772 Reduced 31.49%	290,994 $5.63 Million
Q2 2024 Jul 29, 2024	SELL	$21.87 - $28.24 $1.3 Million - $1.68 Million	-59,354 Reduced 12.26%	424,766 $11 Million
Q1 2024 Apr 29, 2024	BUY	$27.21 - $39.48 $1.97 Million - $2.85 Million	72,273 Added 17.55%	484,120 $13.8 Million
Q4 2023 Feb 07, 2024	BUY	$21.2 - $31.03 $2,650 - $3,878	125 Added 0.03%	411,847 $12.6 Million
Q3 2023 Nov 02, 2023	SELL	$26.2 - $36.08 $192,308 - $264,827	-7,340 Reduced 1.75%	411,722 $11.1 Million
Q2 2023 Aug 07, 2023	SELL	$25.16 - $41.38 $627,867 - $1.03 Million	-24,955 Reduced 5.62%	419,062 $14.9 Million
Q1 2023 May 09, 2023	BUY	$23.68 - $38.51 $261,900 - $425,920	11,060 Added 2.55%	444,017 $11.3 Million
Q4 2022 Feb 09, 2023	BUY	$28.0 - $40.56 $132,692 - $192,213	4,739 Added 1.11%	432,957 $17.6 Million
Q3 2022 Nov 09, 2022	SELL	$29.63 - $48.31 $153,098 - $249,617	-5,167 Reduced 1.19%	428,218 $14.2 Million
Q2 2022 Aug 10, 2022	BUY	$27.79 - $50.61 $1.51 Million - $2.75 Million	54,310 Added 14.33%	433,385 $15.3 Million
Q1 2022 May 09, 2022	SELL	$39.62 - $69.97 $1.93 Million - $3.42 Million	-48,833 Reduced 11.41%	379,075 $17.4 Million
Q4 2021 Feb 09, 2022	SELL	$58.09 - $82.51 $865,947 - $1.23 Million	-14,907 Reduced 3.37%	427,908 $28.4 Million
Q3 2021 Nov 09, 2021	SELL	$58.38 - $84.96 $4.34 Million - $6.32 Million	-74,352 Reduced 14.38%	442,815 $27.6 Million
Q2 2021 Aug 10, 2021	SELL	$62.15 - $90.32 $40,583 - $58,978	-653 Reduced 0.13%	517,167 $42.8 Million
Q1 2021 May 10, 2021	BUY	$61.35 - $90.47 $10.6 Million - $15.7 Million	173,082 Added 50.21%	517,820 $34.3 Million
Q4 2020 Feb 08, 2021	BUY	$43.82 - $85.37 $567,381 - $1.11 Million	12,948 Added 3.9%	344,738 $26.5 Million
Q3 2020 Nov 06, 2020	SELL	$33.21 - $51.27 $336,350 - $519,262	-10,128 Reduced 2.96%	331,790 $14.3 Million
Q2 2020 Aug 05, 2020	SELL	$26.12 - $43.27 $1.07 Million - $1.77 Million	-40,952 Reduced 10.7%	341,918 $14.8 Million
Q1 2020 May 12, 2020	SELL	$20.56 - $63.12 $2.61 Million - $8 Million	-126,800 Reduced 24.88%	382,870 $11 Million
Q4 2019 Feb 05, 2020	SELL	$28.14 - $73.01 $8.85 Million - $23 Million	-314,425 Reduced 38.15%	509,670 $32.3 Million
Q3 2019 Nov 13, 2019	SELL	$26.26 - $34.86 $39,074 - $51,871	-1,488 Reduced 0.18%	824,095 $23.2 Million
Q2 2019 Aug 12, 2019	BUY	$17.43 - $28.82 $13.4 Million - $22.2 Million	768,578 Added 1348.26%	825,583 $21.9 Million
Q1 2019 May 10, 2019	BUY	$12.05 - $20.18 $13,182 - $22,076	1,094 Added 1.96%	57,005 $1.05 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $51,219 - $93,949	-4,769 Reduced 7.86%	55,911 $694,000
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $66,458 - $96,364	4,747 Added 8.49%	60,680 $1.16 Million
Q2 2018 Aug 13, 2018	BUY	$6.37 - $14.02 $356,293 - $784,180	55,933 New	55,933 $0

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account